COMMUNIQUÉS West-GlobeNewswire
-
Argobio launches Enodia with €20.7 million seed financing to advance a small molecule platform for targeted protein degradation enabled by proteomics and machine learning
08/01/2026 -
ENvue Medical to Ring the Nasdaq Opening Bell on Wednesday, January 14th, 2026
08/01/2026 -
Dewpoint Therapeutics Announces TDP-43 Condensate Modulator Development Candidate for Treatment of ALS and Related Neurodegenerative Diseases
08/01/2026 -
Apella Raises $80 Million to Transform the Hospital with Ambient AI and Computer Vision
08/01/2026 -
Recovery First Treatment Center Names Executive Director With 25 Years of Behavioral Healthcare Leadership
08/01/2026 -
CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT
08/01/2026 -
Akari Therapeutics to Present at the 2026 Biotech Showcase
08/01/2026 -
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
08/01/2026 -
Synfini Opens Cloud Access to its Agile AI Foundry to Accelerate Discovery of Better Molecules
08/01/2026 -
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
08/01/2026 -
PacBio and UC Davis Researchers Introduce CiFi, a New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from a Single SMRT Cell
08/01/2026 -
Lynn Stockwell and Bright Green Corporation File $3 Billion Lawsuit Against Rodey Law Firm and Attorneys’ Liability Assurance Society (ALAS) for Legal Malpractice and Bad Faith
08/01/2026 -
Omada Health’s GLP-1 Behavior Change Companion Programs Help Drive Lasting, Long-Term Weight Loss
08/01/2026 -
Marius Pharmaceuticals to Initiate Study Evaluating KYZATREX® (testosterone undecanoate) CIII Capsules in Men Ages 65–80
08/01/2026 -
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
08/01/2026 -
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
08/01/2026 -
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
08/01/2026 -
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
08/01/2026 -
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
08/01/2026
Pages